Corvus Pharmaceuticals: Steady As She Goes (NASDAQ:CRVS)
· seekingalpha.com
Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.
We checked on Corvus Pharmaceuticals, Inc. ( CRVS ) in March of last year , and we basically said everything seemed to be lining up for their lead compound, soq...